Floatz logo

gsk2110183

Solid Tumor

Laekna LimitedPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
59/ 100

Competitive context

927 Active assets in the Solid Tumor cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

gsk2110183 is also rated in:

ovarian cancerDormant
BB
Indicative ·
64 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →
cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →